TR201812823T4 - Lipopeptit bileşimleri ve ilgili yöntemler. - Google Patents

Lipopeptit bileşimleri ve ilgili yöntemler. Download PDF

Info

Publication number
TR201812823T4
TR201812823T4 TR2018/12823T TR201812823T TR201812823T4 TR 201812823 T4 TR201812823 T4 TR 201812823T4 TR 2018/12823 T TR2018/12823 T TR 2018/12823T TR 201812823 T TR201812823 T TR 201812823T TR 201812823 T4 TR201812823 T4 TR 201812823T4
Authority
TR
Turkey
Prior art keywords
related methods
lipopeptide compositions
compositions
daptomycin
lipopeptide
Prior art date
Application number
TR2018/12823T
Other languages
English (en)
Turkish (tr)
Inventor
Sun Sophie
Naik Gaauri
O'connor Sandra
Original Assignee
Cubist Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201812823(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals Llc filed Critical Cubist Pharmaceuticals Llc
Publication of TR201812823T4 publication Critical patent/TR201812823T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TR2018/12823T 2009-11-23 2010-11-23 Lipopeptit bileşimleri ve ilgili yöntemler. TR201812823T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
TR201812823T4 true TR201812823T4 (tr) 2019-02-21

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/12823T TR201812823T4 (tr) 2009-11-23 2010-11-23 Lipopeptit bileşimleri ve ilgili yöntemler.

Country Status (33)

Country Link
US (3) US8835382B2 (https=)
EP (2) EP2504353B2 (https=)
JP (3) JP6041673B2 (https=)
CN (3) CN102712677B (https=)
AR (2) AR079127A1 (https=)
AU (1) AU2010321531C1 (https=)
BR (1) BR112012012406B1 (https=)
CA (1) CA2781666C (https=)
CL (2) CL2012001336A1 (https=)
CO (1) CO6541585A2 (https=)
CR (1) CR20120271A (https=)
CY (1) CY1120854T1 (https=)
DK (1) DK2504353T4 (https=)
DO (1) DOP2012000140A (https=)
EC (1) ECSP12011939A (https=)
ES (1) ES2686331T5 (https=)
FI (1) FI2504353T4 (https=)
HR (1) HRP20181380T4 (https=)
HU (1) HUE039967T2 (https=)
IL (1) IL219891B (https=)
LT (1) LT2504353T (https=)
MX (1) MX2012005993A (https=)
NZ (1) NZ600118A (https=)
PE (2) PE20151717A1 (https=)
PL (1) PL2504353T5 (https=)
PT (1) PT2504353T (https=)
RS (1) RS57566B2 (https=)
RU (1) RU2607526C2 (https=)
SG (1) SG10201407724YA (https=)
SI (1) SI2504353T2 (https=)
TR (1) TR201812823T4 (https=)
TW (2) TWI606838B (https=)
WO (1) WO2011063419A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
US8709310B2 (en) 2011-01-05 2014-04-29 Hospira, Inc. Spray drying vancomycin
RU2013157188A (ru) * 2011-05-26 2015-07-10 Кьюбист Фармасьютикалз, Инк. Композиции св-183,315 и относящиеся к ним способы
CA2863291A1 (en) * 2012-01-12 2013-07-18 Celgene Corporation Romidepsin formulations and uses thereof
ES2655215T3 (es) * 2012-08-23 2018-02-19 Mylan Laboratories Ltd. Mejoramiento de la formulación inyectable de daptomicina
US9655946B2 (en) 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
RU2770366C2 (ru) 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
JP7582205B2 (ja) * 2019-12-26 2024-11-13 ニプロ株式会社 ダプトマイシンを含有する安定した凍結乾燥製剤
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
EP4117625A1 (en) * 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
SU1452484A3 (ru) 1984-10-09 1989-01-15 Эли Лилли Энд Компани (Фирма) Способ получени производных антибиотиков А-21978С, штамм стрептомицета SтRертомYсеS RoSeoSpoRUS, используемый дл получени антибиотических веществ А-21978С
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
IL93618A0 (en) * 1989-03-06 1990-12-23 Lilly Co Eli Improved diluent formulation for daptomycin
DK0438813T3 (da) 1990-01-26 1998-07-27 Hoechst Ag Nyt antibiotikum, deoxymulundocandin, en fremgangsmåde til dets fremstilling samt dets anvendelse som lægemiddel
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (https=) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
DK0640095T3 (da) 1992-04-20 1999-04-12 Abbott Lab Fremgangsmåde til fremstilling af vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
PL203689B1 (pl) 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO2001044274A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
PL218223B1 (pl) * 2000-06-21 2014-10-31 Cubist Pharmaceuticals Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重t細胞エピトープポリペプチドの酢酸塩組成物
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
KR20040032891A (ko) 2001-08-06 2004-04-17 큐비스트 파마슈티컬즈 인코포레이티드 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및방법
ATE325140T1 (de) 2002-01-17 2006-06-15 Arkema Supramolekularpolymere
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−11含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
CA2597812C (en) * 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
JP2008546429A (ja) 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ, インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
WO2007099396A2 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ES2401299T5 (es) * 2006-07-26 2016-04-06 Sandoz Ag Formulaciones de caspofungina
DK2084519T3 (da) 2006-10-10 2012-08-20 Los Alamos Nat Security Llc Røntgenfluorescens-analysefremgangsmåde
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Hgf製剤
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
CA2692053A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
AU2008317307A1 (en) * 2007-10-25 2009-04-30 Novartis Ag Powder conditioning of unit dose drug packages
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2011062676A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
CN103379917B (zh) 2010-11-01 2016-10-12 梅琳塔治疗公司 药物组合物
US20120202823A1 (en) 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法

Also Published As

Publication number Publication date
HRP20181380T1 (hr) 2018-10-19
US8835382B2 (en) 2014-09-16
NZ600118A (en) 2014-08-29
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
ES2686331T5 (es) 2024-03-27
CA2781666A1 (en) 2011-05-26
AR079127A1 (es) 2011-12-28
WO2011063419A3 (en) 2011-10-13
DOP2012000140A (es) 2012-10-30
MX2012005993A (es) 2012-11-23
SG10201407724YA (en) 2014-12-30
JP6041673B2 (ja) 2016-12-14
EP2504353A2 (en) 2012-10-03
JP2013511557A (ja) 2013-04-04
EP2504353B2 (en) 2023-09-13
US9662397B2 (en) 2017-05-30
CN104056250A (zh) 2014-09-24
LT2504353T (lt) 2018-09-25
AU2010321531A1 (en) 2012-06-14
PE20121517A1 (es) 2012-11-26
CN108785654A (zh) 2018-11-13
PL2504353T5 (pl) 2023-11-20
RS57566B1 (sr) 2018-10-31
IL219891B (en) 2018-01-31
EP3417849A1 (en) 2018-12-26
CL2012001336A1 (es) 2012-10-05
BR112012012406A2 (pt) 2019-12-03
TW201703791A (zh) 2017-02-01
CL2015002412A1 (es) 2016-02-05
CY1120854T1 (el) 2019-12-11
ES2686331T3 (es) 2018-10-17
US9138456B2 (en) 2015-09-22
SI2504353T1 (sl) 2018-10-30
JP6088681B2 (ja) 2017-03-01
RS57566B2 (sr) 2023-12-29
JP6239167B2 (ja) 2017-11-29
HUE039967T2 (hu) 2019-02-28
DK2504353T3 (en) 2018-09-10
CO6541585A2 (es) 2012-10-16
EP2504353A4 (en) 2014-04-02
US20120270772A1 (en) 2012-10-25
US20160030577A1 (en) 2016-02-04
CN102712677B (zh) 2015-06-03
JP2016147874A (ja) 2016-08-18
RU2012126076A (ru) 2013-12-27
ECSP12011939A (es) 2012-07-31
CR20120271A (es) 2012-08-01
SI2504353T2 (sl) 2023-11-30
WO2011063419A2 (en) 2011-05-26
RU2607526C2 (ru) 2017-01-10
FI2504353T4 (fi) 2023-11-30
PL2504353T3 (pl) 2018-11-30
PE20151717A1 (es) 2015-11-19
AR123846A2 (es) 2023-01-18
AU2010321531A2 (en) 2014-10-30
JP2017075186A (ja) 2017-04-20
TWI548414B (zh) 2016-09-11
CA2781666C (en) 2017-02-21
PT2504353T (pt) 2018-10-18
BR112012012406B1 (pt) 2021-11-16
EP2504353B1 (en) 2018-07-11
AU2010321531C1 (en) 2020-10-01
US20140364380A1 (en) 2014-12-11
AU2010321531B2 (en) 2016-11-03
DK2504353T4 (da) 2023-11-20
IL219891A0 (en) 2012-07-31
HRP20181380T4 (hr) 2023-11-10
CN102712677A (zh) 2012-10-03

Similar Documents

Publication Publication Date Title
TR201812823T4 (tr) Lipopeptit bileşimleri ve ilgili yöntemler.
EP3957711A3 (en) Detergent composition comprising amylase and protease variants
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
EA201201036A1 (ru) Целевые геномные изменения
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
IN2014DN09346A (https=)
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX395271B (es) Composicion farmaceutica.
MY181898A (en) Heterocyclic compounds and uses thereof
EA201201000A1 (ru) Способы лечения колоректального рака
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
DK2814504T3 (da) Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX392434B (es) Particulas porosas de oxido inorganico y metodos para preparar y utilizar los mismos.
EA201270377A1 (ru) Стабильные композиции sns-595 и способы их получения
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
WO2012174164A3 (en) Agonists of gpr131 and uses thereof
IT1401950B1 (it) Composizioni di (co)polimeri vinilaromatici espansibili autoestinguenti e procedimento per la loro preparazione.
TR201109160A2 (tr) Eplerenon içeren yeni farmasötik kompozisyonlar.
GB2509470A (en) Pharmaceutical compositions of antihypertensives
HK1178742A1 (zh) S-亚硝基谷胱甘肽还原酶的新抑制剂